title: [An alternative Abl-kinase inhibitor overcomes imatinib resistance mutations of Bcr-Abl oncogenes].
authors.affiliation: III. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar der Technischen Universität München. n.bubnoff@lrz.tum.de
authors.forename: N
authors.initials: N
authors.lastname: Von Bubnoff
authors.forename: C
authors.initials: C
authors.lastname: Peschel
authors.forename: J
authors.initials: J
authors.lastname: Duyster
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology*; D001549:Benzamides; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D019008:Drug Resistance, Neoplasm / Q000187:drug effects / Q000235:genetics; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D016313:Genes, abl / Q000187:drug effects*; D006801:Humans; D000068877:Imatinib Mesylate; D051379:Mice; D016297:Mutagenesis, Site-Directed; D010879:Piperazines / Q000737:chemistry / Q000494:pharmacology*; D017354:Point Mutation / Q000187:drug effects; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000737:chemistry / Q000494:pharmacology*; D013329:Structure-Activity Relationship
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; C115711:PD 173074; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases
vernacular_title: Ein alternativer Abl-Kinase-Inhibitor hemmt Imatinib-Resistenzmutationen des Bcr-Abl-Onkogens.